A new study has found that the drug bevacizumab offers no survival benefits for patients with newly diagnosed glioblastoma or brain tumor. "The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizumab had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong ...
Read More
No comments:
Post a Comment